Showing 1 to 8 of 8 results
EU Approves New, Two-Injection HIV Prevention Treatment
The European Commission approved Gilead's new HIV prevention injection, Yeytuo, requiring only two annual injections, offering improved prevention for at-risk populations, especially in developing countries, where a deal ensures low-cost access, despite an initial high price.
EU Approves New, Two-Injection HIV Prevention Treatment
The European Commission approved Gilead's new HIV prevention injection, Yeytuo, requiring only two annual injections, offering improved prevention for at-risk populations, especially in developing countries, where a deal ensures low-cost access, despite an initial high price.
Progress
36% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
Progress
40% Bias Score
The Handmaid's Tale": Gilead's Rise and Fall
The Handmaid's Tale" series finale, released during a Republican presidency, depicts Gilead's rise from an environmental disaster and fertility crisis, culminating in a Sons of Jacob coup d'état around 2025 (fan speculation), resulting in a totalitarian theocracy where fertile women are enslaved.
The Handmaid's Tale": Gilead's Rise and Fall
The Handmaid's Tale" series finale, released during a Republican presidency, depicts Gilead's rise from an environmental disaster and fertility crisis, culminating in a Sons of Jacob coup d'état around 2025 (fan speculation), resulting in a totalitarian theocracy where fertile women are enslaved.
Progress
52% Bias Score
Annual Lenacapavir Injection Shows Promise in HIV Prevention
A phase 1 study shows that a single annual injection of lenacapavir, an HIV antiviral drug, resulted in blood concentrations sufficient to potentially prevent HIV infection, offering a promising new approach to prevention.
Annual Lenacapavir Injection Shows Promise in HIV Prevention
A phase 1 study shows that a single annual injection of lenacapavir, an HIV antiviral drug, resulted in blood concentrations sufficient to potentially prevent HIV infection, offering a promising new approach to prevention.
Progress
44% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved Lenacapavir (Yeytuo), a twice-yearly HIV prevention injection, following a positive EMA recommendation and successful clinical trials showing 100% effectiveness; this comes amidst a rise in HIV cases in the EU and global efforts to combat the disease.
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved Lenacapavir (Yeytuo), a twice-yearly HIV prevention injection, following a positive EMA recommendation and successful clinical trials showing 100% effectiveness; this comes amidst a rise in HIV cases in the EU and global efforts to combat the disease.
Progress
48% Bias Score
FDA Approves Twice-Yearly Injectable HIV Prevention Treatment
The FDA approved Yeztugo, Gilead's new twice-yearly injectable HIV prevention treatment, on June 18, 2025, showing over 99.9% efficacy in clinical trials involving over 4,000 participants across diverse populations, but concerns remain about its high potential cost.
FDA Approves Twice-Yearly Injectable HIV Prevention Treatment
The FDA approved Yeztugo, Gilead's new twice-yearly injectable HIV prevention treatment, on June 18, 2025, showing over 99.9% efficacy in clinical trials involving over 4,000 participants across diverse populations, but concerns remain about its high potential cost.
Progress
52% Bias Score
The Handmaid's Tale" Season Six: Rebellion and Uncertain Conclusion
The final season of "The Handmaid's Tale" features June's return to Gilead to fight against the regime alongside Luke and Moira, while Serena attempts reform, Nick faces internal conflict, and Janine faces consequences for her defiance; the season's ending is expected to be ambiguous.
The Handmaid's Tale" Season Six: Rebellion and Uncertain Conclusion
The final season of "The Handmaid's Tale" features June's return to Gilead to fight against the regime alongside Luke and Moira, while Serena attempts reform, Nick faces internal conflict, and Janine faces consequences for her defiance; the season's ending is expected to be ambiguous.
Progress
36% Bias Score
Lenacapavir: A Highly Effective but Expensive HIV Drug
Lenacapavir, a new HIV drug from Gilead, offers near-100% efficacy with twice-yearly injections but faces accessibility challenges due to its $40,000 annual cost, although Gilead is negotiating lower prices in 120 low-income countries.
Lenacapavir: A Highly Effective but Expensive HIV Drug
Lenacapavir, a new HIV drug from Gilead, offers near-100% efficacy with twice-yearly injections but faces accessibility challenges due to its $40,000 annual cost, although Gilead is negotiating lower prices in 120 low-income countries.
Progress
60% Bias Score
Showing 1 to 8 of 8 results